Trial Profile

A Two-part, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of APG777 in Patients With Moderate-to-severe Atopic Dermatitis

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 15 Oct 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Zumilokibart (Primary) ; Lebrikizumab
Indications Atopic dermatitis
Focus Proof of concept; Therapeutic Use
Acronyms APEX
Sponsors Apogee Therapeutics

Most Recent Events

30 Sep 2026 According to an AbbVie Media Release, data from this study will be presented as a late-breaker presentation at the 2026 Annual European Academy of Dermatology and Venereology (EADV) Congress in Vienna.
30 Sep 2026 Results presented in an AbbVie Media Release.
10 Aug 2026 Results presented in the Apogee Therapeutics media release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com